Chemomab Therapeutics Ltd. (CMMB) stock
CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.55−0.09 (-5.49%)
Close on Nov 18, 2026Market cap $11.15MP/E 1.1Yield –
Chemomab Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$112.00M. The highest annual figure on record is -$4.64M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$112.00M | – |
| FY2024 | Dec 31, 2024 | -$103.00M | – |
| FY2018 | Dec 31, 2018 | -$13.04M | – |
| FY2017 | Dec 31, 2017 | -$9.39M | – |
| FY2016 | Dec 31, 2016 | -$4.64M | – |
See a number that looks wrong?